Current Treatment Options in Oncology

, Volume 8, Issue 6, pp 428–434

Angiosarcomas and Taxanes

Authors

    • Département de Cancérologie GénéraleCentre Oscar Lambret
    • Equipe d’Accueil 2694: Santé Publique, Epidémiologie et modélisation des maladies chroniquesUniversité Lille II
  • Amélie Lansiaux
    • Laboratoire de Pharmacologie Anti-tumoraleCentre Oscar Lambret
  • Antoine Adenis
    • Département de Cancérologie Digestive et UrologiqueCentre Oscar Lambret
Soft Tissue

DOI: 10.1007/s11864-007-0042-0

Cite this article as:
Penel, N., Lansiaux, A. & Adenis, A. Curr. Treat. Options in Oncol. (2007) 8: 428. doi:10.1007/s11864-007-0042-0

Opinion statement

Angiosarcomas (AS) are a heterogeneous group of rare and aggressive malignancies. The best treatment of localized AS includes wide resection following by adjuvant radiation therapy as possible. The current standard treatment of metastatic AS remains a doxorubicin-based regimen. This treatment provides a median progression-free survival and a median overall survival of about 4 and 8 months, respectively. Numerous case reports and retrospective studies have suggested that taxanes (paclitaxel or docetaxel) may provide some objective responses. The French Sarcoma Group has conducted a phase II clinical trial, which states the benefit of weekly paclitaxel in patients with unresectable or metastatic AS. After 2 cycles, the non-progression rate was 78% and complete histological responses were observed in 3 out of 30 cases. Further clinical studies are needed to confirm clinic impact of weekly paclitaxel on survival and to assess the role of taxanes in the multidisciplinary treatment of AS.

Copyright information

© Current Science Inc. 2007